Aethlon Medical, Inc. (NASDAQ:AEMD) Shares Shorted: Short Interest Down 56.4% in October

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 32,925 shares, a decline of 56.4% from the September 30th total of 75,446 shares. Currently, 4.7% of the company’s shares are short sold. Based on an average daily trading volume, of 57,317 shares, the days-to-cover ratio is currently 0.6 days.

Aethlon Medical Stock Down 4.6%

AEMD traded down $0.26 during midday trading on Friday, hitting $5.26. 6,744 shares of the company were exchanged, compared to its average volume of 829,991. The firm’s 50 day moving average price is $4.42 and its 200-day moving average price is $7.82. Aethlon Medical has a 1-year low of $1.41 and a 1-year high of $26.90. The firm has a market capitalization of $3.74 million, a P/E ratio of -0.15 and a beta of 1.21.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). On average, sell-side analysts predict that Aethlon Medical will post -5.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Thursday, October 15th. HC Wainwright reiterated a “neutral” rating on shares of Aethlon Medical in a research note on Friday, September 18th. Finally, Wall Street Zen raised Aethlon Medical to a “sell” rating in a report on Saturday, October 17th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $1.50.

Aethlon Medical Company Profile

Aethlon Medical, Inc is a biotechnology and medical-device company focused on developing extracorporeal blood filtration technologies for life-threatening diseases. The company’s lead product candidate, the Hemopurifier, is designed to selectively remove harmful substances from the bloodstream, including cancer-promoting exosomes and certain viral particles.

The Hemopurifier is intended to be used with standard dialysis or blood-circulation equipment and is being investigated for potential applications in oncology and infectious disease.